An Open-Label Pilot Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents
Latest Information Update: 07 Nov 2021
Price :
$35 *
At a glance
- Drugs Lurasidone (Primary)
- Indications Asperger syndrome; Autistic disorder; Bipolar I disorders; Bipolar II disorders; Major depressive disorder; Mood disorders; Pervasive child development disorders; Psychotic disorders; Schizoaffective disorder; Schizophrenia
- Focus Adverse reactions
- 21 Dec 2012 New trial record
- 01 Dec 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.